Dose individualization of intravenous busulfan in pediatric patients undergoing bone marrow transplantation: impact and in vitro evaluation of infusion lag-time.
E NeroutsosI AthanasiadouA PaisiouK ZisakiE GoussetisH ArchontakiP TsirigotisM KitraS GrafakosA SpyridonidisAristides DokoumetzidisGeorgia ValsamiPublished in: The Journal of pharmacy and pharmacology (2022)
TDM, applied successfully to 76 children, confirmed the need for Busulfan dose-individualization in paediatric patients. Infusion lag-time was proved clinically significant for younger, low body-weight patients and those close to the lower therapeutic-range limit.
Keyphrases
- end stage renal disease
- patients undergoing
- bone marrow
- newly diagnosed
- body weight
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- low dose
- emergency department
- mesenchymal stem cells
- intensive care unit
- young adults
- stem cells
- high dose
- allogeneic hematopoietic stem cell transplantation
- cell therapy
- patient reported